Literature DB >> 25301331

Concealed dagger in FLT3/ITD+ AML.

Yishai Ofran1.   

Abstract

In this issue of Blood, Ostronoff et al report a low remission rate in acute myeloid leukemia (AML) patients coexpressing FLT3/ITD and cryptic translocation t(5;11)(q35;p15.5), known as NUP98/NSD1.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25301331     DOI： 10.1182/blood-2014-09-597690

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  4 in total

1.  Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Authors:  Jarno L Kivioja; Angeliki Thanasopoulou; Ashwini Kumar; Mika Kontro; Bhagwan Yadav; Muntasir M Majumder; Komal K Javarappa; Samuli Eldfors; Juerg Schwaller; Kimmo Porkka; Caroline A Heckman
Journal:  Leukemia       Date:  2018-12-19       Impact factor: 11.528

Review 2.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

3.  A point mutation of zebrafish c-cbl gene in the ring finger domain produces a phenotype mimicking human myeloproliferative disease.

Authors:  X Peng; M Dong; L Ma; X-E Jia; J Mao; C Jin; Y Chen; L Gao; X Liu; K Ma; L Wang; T Du; Y Jin; Q Huang; K Li; L I Zon; T Liu; M Deng; Y Zhou; X Xi; Y Zhou; S Chen
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

4.  DesA Prognostic Risk Model of LncRNAs in Patients With Acute Myeloid Leukaemia Based on TCGA Data.

Authors:  Weidong Ding; Yun Ling; Yuan Shi; Zhuojun Zheng
Journal:  Front Bioeng Biotechnol       Date:  2022-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.